Business, energy, technology, markets and global industry news from Business News Today

Scribe Therapeutics

PharmaDeviceNews Scribe Therapeutics
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Representative image: Scientists analyze CRISPR gene-editing and liver-targeted cardiometabolic research data in a biotech laboratory, reflecting Scribe Therapeutics’ push to advance epigenetic silencing for durable LDL-C reduction.
Pharma & Biotech

Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs

CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.

Read More
Pharma & Biotech

Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone

Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.

Read More